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56BACKGROUND & AIMS: Noninvasive methods are
needed to identify clinically significant portal hyperten-
sion (CSPH) and esophageal varices (EVs) in patients with
compensated cirrhosis. We looked for markers of the
presence of CSPH and EVs in patients with cirrhosis.
METHODS: We performed a cross-sectional study that
included a training set of 117 patients with compensated
cirrhosis, confirmed by histology, from a tertiary referral
center. Spleen diameter was measured by ultrasound and
liver stiffness (LS) was measured by transient elastogra-
phy; endoscopy was used as the standard for detection of
EVs and measurements of hepatic venous pressure gradi-
ent were used as the standard for identifying CSPH. We
assessed the ability of platelet count, spleen diameter, LS,
and combinations of these factors (ie, ratio of platelet
count to spleen size, and LS  spleen size/platelet count
[LSPS]) to identify patients with CSPH and EV. The anal-
ysis included 2 new statistical models: the PH risk score
and the varices risk score. Results were validated using an
independent series of 56 patients with compensated pa-
tients from another center. RESULTS: LS was the best
single noninvasive variable for identifying patients with
CSPH (area under the receiver operating characteristic,
0.883; 95% confidence interval [CI], 0.824–0.943; P 
.0001). The area under the receiver operating characteris-
tic value increased when LS was combined with platelet
count and spleen size, either as LSPS (0.918; 95% CI,
0.8720.965; P  .0001) or PH risk score (0.935; 95% CI,
0.893–0.977; P  .0001). More than 80% of patients were
accurately classified using LSPS and PH risk score. Anal-
yses of the varices risk score and LSPS were superior to
all other noninvasive tests for identifying patients with
EVs (area under the receiver operating characteristic,
0.909; 95% CI, 0.8410.954 and 0.882; 95% CI, 0.810–
0.935, respectively); they correctly classified 85% of pa-
tients in the training set and 75% in the validation set.
CONCLUSIONS: Combined data on LS, spleen di-
ameter, and platelet count can be used to identify
patients with compensated cirrhosis most likely to
have CSPH and EV.
Keywords: HVPG; Predictive Models; Prognostic Factor;
Liver Disease.Portal hypertension constitutes the pathophysiologicalbasis of most complications of cirrhosis. A portal
ressure gradient 10 mm Hg, as estimated by hepatic
enous pressure gradient (HVPG), is necessary for the
evelopment of esophageal varices (EVs),1 ascites, and all
other complications of this syndrome. The term clinically
significant portal hypertension has been coined to name this
condition, which is invariably found in patients with
decompensated disease.
On the contrary, only about 50% to 70% of patients
with compensated cirrhosis show clinically significant
portal hypertension (CSPH)1; in this setting, CSPH is an
ndependent predictor of clinical decompensation2; this
olds true also for patients with potentially resectable
epatocellular carcinoma.3 In turn, the presence of EVs is
an independent predictor of mortality4 and this has led to
the recommendation that all patients with compensated
cirrhosis be investigated for the presence of gastroesoph-
ageal varices5 and CSPH should ideally be diagnosed or
uled out.
Because the diagnoses of EVs and CSPH require endos-
opy and hepatic vein catheterization, which are invasive
nd need specific expertise, there is a need for noninvasive,
imple, objective, reproducible, and accurate methods to
redict the presence of CSPH and of EVs in patients with
ompensated cirrhosis.
The most commonly reported parameters associated
ith CSPH and EVs in compensated patients include
igns of hypersplenism, such as low platelet count,6–12
large spleen size,7,10,13 or their combination (platelet to
spleen ratio),14 dilatation of the portal vein system or
presence of collaterals on ultrasound8,15,16 and increase in
the Child-Pugh score.6,8,9,17 However, none of these meth-
ds were accurate enough when tested in independent
alidation series,5,13 and some of them, such as a complete
assessment of the portal vein system by ultrasound, were
Abbreviations used in this paper: AUROC, area under the receiver
operating characteristic curve; CI, conﬁdence interval; CSPH, clinically
signiﬁcant portal hypertension; EV, esophageal varices; HVPG, hepatic
venous pressure gradient; INR, International Normalized Ratio; LR,
likelihood ratio; LS, liver stiffness; LSPS, liver stiffness  spleen diam-
eter to platelet ratio.
© 2013 by the AGA Institute
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114not easy to perform and required specific long-term train-
ing.18
More recently, transient elastography, which estimates
liver stiffness (LS), has been proposed as a new method to
noninvasively diagnose CSPH and EVs in patients with
cirrhosis. While the accuracy of LS in predicting CSPH
seems good, its discriminative ability in the prediction of
EVs appears inadequate.19
The combination of different methods might amelio-
rate the accuracy of single tests by assessing different
pathophysiological components of portal hypertension.
Recently, the combination of 3 simple methods—LS,
spleen size, and platelet count (LSPS)—in a single score
showed high accuracy for diagnosing and ruling out EVs
in patients with compensated hepatitis B virusrelated
hronic liver disease20; however, this score has not been
tested for the prediction of CSPH and there are no data
on its ability to identify varices in patients with different
etiologies of liver disease.
We aimed at comparing the accuracy of simple rou-
tinely available noninvasive parameters and their combi-
nation for identifying CSPH and presence of EVs in pa-
tients with compensated cirrhosis. For this aim, the
results of noninvasive tests were compared with those of
the measurement of HVPG (ie, the gold standard for the
diagnosis of CSPH) and upper gastrointestinal endoscopy
(ie, the gold standard for diagnosing esophagogastric var-
ices).
Methods
This study was approved by the Ethics Committee of
each participating center. The nature of the study was explained
to the patients and a written informed consent was obtained in
each case according to the principles of the Declaration of
Helsinki (revision of Edinburgh 2000).
Patients
Training set. The training set was composed by 117
atients with compensated cirrhosis requiring measurement of
VPG with the aim of diagnosing or excluding CSPH, included
n 3 prospective studies carried out at Hospital Clínic, Barcelona
etween May 2007 and September 2011 (Berzigotti et al,21 Llop
t al,22 and CITRO study, ongoing) in which all noninvasive
arameters under investigation were available. Valid LS measure-
ents could not be obtained in 14 (10.7%) of the 131 patients
nitially evaluated due to obesity (n  8, no valid shot) or
unreliable results (n  3, success rate 60%; n  3, interquartile
range/median 30%). This prevented the inclusion of these 14
patients in the study.
Sixty-three patients (53.8%) had a single nodule of hepatocel-
lular carcinoma (diameter: 31  19 mm), potentially susceptible
of surgical resection. Multifocal hepatocellular carcinoma was
ruled out in all 63 patients by hepatic magnetic resonance
imaging according to international guidelines.23
Cirrhosis was biopsy-proven in all cases. Transjugular liver
biopsy was performed during hepatic vein catheterization under
x-ray videofluoroscopy through either aspiration technique (15G
needle; Cook Europe, Bjaeverskov, Denmark) or, in the case of
small or fragmented specimen, by a Tru-Cut needle (18G Tru-
Cut needle; Cook Europe). Passes of the needle were repeatedntil a satisfactory sample (at least 15 mm of length in total) was
btained.24 Specimens were processed and stained with H&E
and Masson’s trichromic, and fibrosis was scored according to
Ishak score by an expert pathologist unaware of the condition of
the patient and of the study protocol and skilled in the inter-
pretation of transjugular liver samples.
According to the protocol of each study, patients were as-
sessed on the same day by HVPG and transient elastography.
Exclusion criteria were previous or ongoing decompensation
of liver disease (ie, ascites, bleeding, hepatic encephalopathy, or
jaundice), portal vein thrombosis, multifocal hepatocellular car-
cinoma, and previous or ongoing treatment for portal
hypertension.
Validation set. The validation set was composed of 56
patients with compensated advanced chronic liver disease (50
with biopsy-proven cirrhosis and 6 with F3 fibrosis but sus-
pected of having cirrhosis on clinical grounds) requiring mea-
surement of HVPG with the aim of diagnosing or excluding
CSPH, consecutively observed in a referral University Hospital in
a different European Country (Florence, Italy). Exclusion criteria
were similar to those of the training set. None of the patients
included in the validation set had hepatocellular carcinoma.
Laboratory Parameters
Laboratory parameters were obtained on the day of
HVPG measurement and included albumin, bilirubin, Interna-
tional Normalized Ratio (INR), renal function, electrolytes, he-
moglobin, hematocrit, leukocyte and platelet count, cholesterol,
alanine aminotransferase, aspartate aminotransferase, alkaline
phosphatase, and -glutamyltransferase. Child-Pugh score was
alculated.25
Spleen Size
Spleen size is routinely measured and reported on ultra-
sound examinations at both our center and the validation set
center.18 For the current study, spleen size was recorded as it
appeared in the last abdominal ultrasound, which, in 70%, was
within 1 week of HVPG, and in all cases within 3 months of
HVPG. Spleen size was assessed as spleen bipolar diameter
(crossing the spleen hilium) using last-generation equipment
(ACUSON Sequoia 512; Siemens Medical Solutions USA Inc.,
Malvern, PA or SONOLINE Antares; Toshiba Aplio SSA 270,
Tokyo, Japan) with a 3.5-MHz multifrequency sector or convex
probe, following published guidelines.18 Operators were experi-
nced in ultrasound and not aware of the hemodynamic data of
he patients.
LS by Transient Elastography
LS was evaluated by transient elastography (Fibroscan;
Echosens, Paris, France) in the morning in a fasted state.26
Measurements of LS were performed on the right lobe of the
liver through intercostal spaces on patients lying in the dorsal
decubitus position with the right arm in maximal abduction.
The tip of the probe transducer was placed on the skin between
the ribs at the level of the right hepatic lobe. The operator,
assisted by an ultrasonic time-motion image, located a liver
portion of at least 6-cmthick and free of large vascular struc-
tures. Ten successful measurements were performed on each
patient. Success rate was calculated as the ratio of the number of
successful measurements over the total number of acquisitions.
Only LS measurements with a success rate of at least 60% and an
interquartile range 30% were considered reliable. Results are
expressed in kilopascals and median value was used as represen- 115
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AQ: 10tative of LS. The whole examination duration was about 5
minutes.
Combination of Noninvasive Methods
Platelet to spleen ratio was calculated as described pre-
viously by Giannini and colleagues as the ratio between platelet
number/mm3 and bipolar diameter of the spleen in millime-
ers.14 Similarly, spleen to platelet ratio was calculated as the
ratio between bipolar diameter of the spleen in millimeters and
platelet number/mm.20
LSPS was calculated as described previously by Kim and
colleagues as: LS  spleen diameter/platelet ratio.20
Hepatic Hemodynamics and Endoscopy
In the morning, after fasting overnight and immediately
after transient elastography examination, the patients were
transferred to the hepatic hemodynamic laboratory. Under local
anesthesia, an 8F venous catheter introducer was placed in the
right internal jugular vein using the Seldinger technique. Under
fluoroscopic control a 7F balloon-tipped catheter (Edwards Life-
sciences, Irvine, CA) was advanced into the right hepatic vein to
measure wedged and free hepatic venous pressures using preca-
librated electromechanical transducer and polygraph (Mac-Lab;
GE Healthcare, Freiburg, Germany). The wedged position was
obtained by inflating the balloon and confirming the occlusion
of the hepatic vein by injecting a small amount of contrast
medium. HVPG was calculated as the difference between wedged
and free hepatic venous pressures.27 All measurements were
erformed in triplicate and permanent tracings were recorded.27
Endoscopy was performed within 6 months of the hemody-
namic evaluation by a small number of endoscopy operators,
experienced in the assessment of patients with cirrhosis. Accord-
ing to international expert recommendations,5 varices were clas-
sified as absent, small (diameter5 mm) and large (diameter5
mm).
In patients with large varices, medical treatment with -block-
rs was initiated after measuring the noninvasive parameters
sed for this study and after measuring HVPG.
Statistical Analysis
This study was designed as a phase III to IV study of
diagnostic tests according to Lijmer et al,28 aimed at investigat-
ng how well the test distinguishes between patients with or
ithout the disease in patients suspected of having the disease
phase III), and how informative a test is considering additional
nformation available at the moment of testing (phase IV).
Noninvasive models to identify CSPH and EVs were built in a
rst set of patients from our center (training set), and subse-
uently validated in a separate, independent set of patients
validation set). To do so, those variables showing a P  .10 at
nivariate analysis (Student t test for parametric variables, and
2 or Fisher’s exact test for frequencies) were included in a
ultivariable backward stepwise logistic regression. The inter-
ction between these variables was also tested. Variables explain-
ng a statistically significant proportion of the variance (P  .1)
ere maintained in the model using the likelihood ratio (LR)
est. The discriminative ability of the different noninvasive
ethods for the identification of CSPH and of presence of EVs
as assessed by means of receiver operating characteristic curve
nalysis and expressed as area under the receiver operating
haracteristic curve (AUROC). Comparison between AUROC
as made using DeLong test. Sensitivity, specificity, positive,
nd negative likelihood ratio (LR and LR) and 95% confi- 0ence intervals (CIs) were calculated. McNemar test was used in
he 2  2 contingency table for assessing differences in the
roportion of misclassified patients with dichotomous cutoffs
f different noninvasive tests. Similarly, McNemar-Bowker test
as used for 3  3 contingency table for assessing differences in
he proportion of misclassified patients with 2 cutoffs of differ-
nt noninvasive tests. In addition, the performance of previously
ublished cutoffs for the identification of CSPH and varices
erived from prospective studies was tested; namely we tested
3.6 kPa29 and 21.1 kPa30,31 for the prediction of CSPH, and
17.6 kPa for the prediction of varices.29
Statistical analysis was performed with SPSS 16.0 package
(SPSS, Chicago, IL), CIA software (v 2.2.0, University of South-
ampton, Southampton, UK) and MedCalc software (version
12.2.1.0, Belgium). The  value was set at 0.05. All P values are
-sided.
Results
CSPH
Table 1 shows the main characteristics of the stud-
ied population. As shown, most patients both in the
training set and in the validation set had viral liver dis-
ease. The prevalence of CSPH was 67% in the training set
and 86% in the validation set.
On univariate analysis, in the training set, patients with
CSPH had a higher prevalence of male sex, worse liver
function (higher bilirubin and INR, lower albumin),
higher LS, lower platelet count, and larger spleen as com-
pared with patients without CSPH (Table 1). Because
platelet count and spleen diameter are thought to reflect
the same clinical consequence of portal hypertension (hy-
persplenism), we performed a first exploratory binary lo-
gistic regression analysis to evaluate which variable
among platelet count, spleen size, and their combination
(platelet count/spleen diameter ratio and spleen diame-
ter/platelet count ratio) better explained the existence of
CSPH. This analysis selected only spleen diameter/platelet
count ratio, which was used in subsequent analysis.
Then, we performed a binary logistic regression includ-
ing 6 variables (ratio events/variables entered: 13:1): bili-
rubin, INR, albumin, LS, spleen diameter/platelet count
ratio, and sex. LS, spleen diameter/platelet count ratio,
and sex were maintained in the final model; similar results
were obtained when bilirubin, INR, and albumin were
substituted by Child-Pugh score.
The equation of the model (PH risk score) is the fol-
lowing:
PH risk score5.953 0.188 LS1.583 sex (1:
male; 0: female)  26.705  spleen diameter/platelet
count ratio
As for the performance of the different noninvasive
variables tested and of the derived PH risk score in pre-
dicting CSPH, in the training set all of them were signif-
icantly associated with CSPH; AUROC were as follows:
spleen diameter: 0.719 (95% CI, 0.6180.819; P  .0001);
platelet count: 0.787 (95% CI, 0.7050.869; P  .0001);
platelet count to spleen diameter ratio14: 0.811 (95% CI,
.7340.889; P  .0001); combination of laboratory vari- 173
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F2ables17: 0.691 (95% CI, 0.5900.792; P  .001), LS: 0.883
(95% CI, 0.8240.943; P  .0001); LSPS: 0.918 (95% CI,
.8720.965; P  .0001); PH risk score: 0.935 (95% CI,
.8930.977; P  .0001).
The parameters with better diagnostic performance for
SPH were LS, LSPS, and PH Risk score (Table 2). In
articular, PH risk score and LSPS had the best discrim-
nating capacity. LSPS was only marginally superior to LS
lone for CSPH (DeLong test: P  .087; Figure 1), while
H Risk score was clearly superior to LS (DeLong test:
 .021), but not statistically different from LSPS (De-
Long test: P  .160; Figure 1). Similar results were ob-
tained when patients were analyzed according to the eti-
ology of liver disease.
As expected, the proportion of patients with LS  13.6
(88 of 117) was significantly higher in patients with CSPH
(91.0% vs 43.6%; P  .0001); the same happened in those
with LS  21.1 kPa (54 of 117; 65.3% with CSPH vs 7.7%
without CSPH; P  .0001). As previously observed by our
group,22 these values indicate that the 13.6 kPa cutoff had
high sensitivity: 91.0% (95% CI, 82.6%95.6%), but low
specificity 56.4% (95% CI, 41.0%70.7%), while the 21.1
kPa cutoff had a 92.3% specificity (95% CI, 79.7%97.3%),
but low sensitivity: 65.4% (95% CI, 54.3%75.0%) for the
prediction of CSPH. The 34 patients with values of LS
Table 1. Main Characteristics of Patients Included in the Trai
CSPH
Training set
(N  117)
Traini
with
(n 
ge, y 60  11 60 
Sex, M/F, n 82/35 50/28
Body mass indexc 26.8  4.7 27.0 
Etiology, HCV/HBV/alcohol/other, n 78/11/16/12 51/4/
Child–Pugh score 5.5 0.8 5.7 
Child–Pugh class, A/B, n 103/14 64/13
Esophageal varices, no/small/large, n 80/23/14 42/22
Hepatic nodule, n (%) 63 (54) 29
Bilirubin, mg/dL 1.2  0.9 1.3 
INR 1.16  0.016 1.20 
Albumin, g/dL 3.8  0.6 3.7 
AST, IU/mL 81  54 92 
ALT, IU/mL 78  52 91 
HVPG, mm Hg 11.9  5.5 14.9 
CSPH, n (%) 78 (67) N
Platelets, n 109/L 137  64 118 
Combination of laboratory variables17 3.77  4.39 4.87 
Liver stiffness, kPa 25.2  16.6 31.4 
Spleen diameter, cm 13.1  3.0 13.9 
Platelet to spleen ratio14 1156  704 922
Spleen to platelet ratio20 0.126  0.096 0.153 
LSPS20 3.53  3.94 4.83 
NOTE. Values are mean  SD unless otherwise indicated.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; F, fe
set; VS, validation set.
aComparison between patients with and without CSPH.
bSix patients had severe (F3) fibrosis and were included because cirrh
cCalculated as kg/m2.between 13.6 and 21.1 kPa (29% of the included popula-tion) cannot be accurately classified, and should be con-
sidered indeterminate.
Table 2 shows the best cutoffs of the tested noninvasive
parameters; as shown, only LSPS and PH risk score al-
lowed identifying a single dichotomic cutoff combining
both a sensitivity and a specificity 80% (respectively 1.72
for LSPS and 0.63 for PH risk score); LS, although close,
did not fulfill this target.
The 1.72 LSPS cutoff classified correctly 98 of 117
(84%) (65 as having CSPH and 33 as not having CSPH),
while 19 (16%) were misclassified (6 false-positive and 13
false-negative results). With the 0.63 PH risk score cutoff,
100 of 117 (85%) patients were well classified (66 as having
CSPH and 34 as not having CSPH), while 17 (15%) were
misclassified (5 false-positive and 12 false-negative re-
sults).
Results in the validation set confirmed the high dis-
criminative power of LS, LSPS, and PH risk score for the
prediction of CSPH (Table 2, Figure 2). In terms of well
classified and misclassified patients, the PH risk score was
significantly superior to the best cutoff (21.1 kPa) of
transient elastography (McNemar test P  .017).
When, instead of using a dichotomic strategy, we
applied a 90% sensitive cutoff to rule out CSPH, and a
90% specific cutoff to rule in CSPH (Figure 2), PH risk
g Set and the Validation Set According to the Presence of
set
H
)
Training set
without CSPH
(n  39) P valuea
Validation set
(N  56)b
VS vs TS,
P value
1 60  10 .757 58  11 .562
32/7 .035 36/20 .443
.3 26.1  5.8 .600 24.7  2.8 .160
/10 27/7/3/2 .086 46/4/6/0 .142
.9 5.1  0.4 .001 6.0  1.3 .001
39/1 .023 39/17 .003
4 38/1/0 .0001 23/14/19 .001
) 34 (85) .0001 0 .001
.0 0.8  0.4 .003 1.3  0.8 .267
.17 1.09  0.09 .0001 1.14  0.18 .532
.6 4.2  0.5 .0001 3.5  0.6 .006
9 75  34 .224 87  64 .530
2 68  47 .198 80  53 .838
.2 6.0  2.2 .0001 15.2  5.7 .0001
NA NA 48 (86) .006
6 175  61 .0001 116  52 .027
.80 1.87  2.76 .0001 4.88  4.45 .155
6.9 13.2  5.8 .0001 27.4  12.1 .377
.1 11.5  2.1 .0001 15.3  2.9 .0001
62 1606  735 .0001 817  443 .001
.106 0.074  0.031 .0001 0.169  0.114 .009
.30 1.02  0.62 .0001 5.02  4.62 .029
le; HBV, hepatitis B virus; HCV, hepatitis C virus; M, male; TS, training
is was suspected on clinical ground.nin
ng
CSP
78
1
4
13
0
/1
(38
1
0
0
5
5
4
A
5
4
1
3
5
0
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osscore showed again the best performance, with a low 231
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portion of indeterminate cases (McNemarBowker
est: PH risk score vs LS: P  .0001 in TS and VS; PH
isk score vs LSPS: P  .025 in the TS and P  .016
n VS).
CSPH in Patients With Hepatic Nodules
Given the importance of diagnosing CSPH in
patients with hepatic nodules,3,23 we performed a suba-
alysis in our 63 patients (29 with CSPH and 34 with-
ut) testing the performance of all noninvasive vari-
bles. AUROCs were as follows: spleen diameter: 0.627 (95%
I, 0.4900.765; P  .084); platelet count: 0.675 (95%
CI, 0.5360.814; P  .017); platelet count to spleen
iameter ratio14: 0.694 (95% CI, 0.5580.830; P 
Table 2. Performance of the Best Tested Noninvasive Method
(n  117) and in the Validation Set (n  56)
AUROC for predicting
CSPH (95% CI)
Cutoff with 80%
Sensitivity, %
Specificity, %
PPV, % NPV, %
LR
LR
Well classified,
%
LS, kPa
Training set 0.883a (0.8240.943) 17.4
P  .0001 82.1 (72.189.0)
76.9 (61.787.4)
87.7 (78.293.4)
68.2 (53.480.0)
3.56 (1.996.37)
0.23 (0.140.39)
80.3
Validation set 0.901 (0.8040.998) Well classified, 80.4%
LSPS20 P  .0001
Training set 0.918b (0.8720.965) 1.72
P  .0001 83.3 (73.590.0)
84.6 (70.392.8)
91.5 (82.896.1)
71.7 (57.582.7)
5.42 (2.5811.38)
0.20 (0.120.33)
83.7
Validation set 0.906 (0.8180.995) Well classified, 85.7%
PH risk score P  .0001
Training set 0.935 (0.8930.977) 0.63
P  .0001 84.6 (75.091.0)
P  vs LS 87.2 (73.394.4)
P  vs LSPS 93.0 (84.697.0)
73.9 (59.784.4)
6.60 (2.9015.04)
0.18 (0.100.30)
85.5
Validation set 0.932 (0.8531.000) Well classified, 87.5%
P  .0001
P  vs LSPS
PV, negative predictive value; PPV, positive predictive value.
e Long test:
aP  .05 vs spleen diameter and platelet count.
bP  .05 vs spleen diameter, platelet count, and platelet to spleen ra.008); combination of laboratory variables17: 0.540 t(95% CI, 0.3840.696; P  .592), LS: 0.850 (95% CI,
0.7510.949; P  .0001); LSPS: 0.852 (95% CI,
0.7570.947; P  .0001); PH risk score: 0.884 (95%
I, 0.7960.973; P  .0001). Again, the 3 best param-
eters were LS, LSPS, and PH risk score but no statistical
difference was found comparing the 3 AUROCs. How-
ever, only PH risk score allowed identifying a cutoff
with 80% sensitivity and specificity, namely 0.190:
sensitivity 80.0% (95% CI, 62.7%90.5%), specificity
84.8% (95% CI, 69.1%93.3%), positive predictive value
82.8% (95% CI, 65.5%92.4%), negative predictive value
82.4% (95% CI, 66.5%91.7%), LR 5.28 (95% CI,
2.3112.07), and LR 0.24 (95% CI, 0.110.49). By
sing this cutoff 82.5% of patients were correctly iden-
or Identifying CSPH (HVPG  10 mm Hg) in the Training Set
utoff with 80%
Specificity, %
Sensitivity, %
PPV, % NPV, %
LR
LR Well classified,
%
Cutoff with 90%
Sensitivity, %
Specificity, %
PPV, % NPV, %
LR
LR
Well classified,
%
Cutoff with 90%
Specificity, %
Sensitivity, %
PPV, % NPV, %
LR
LR Well classified,
%
17.8 13.0 20.6
4.6 (70.392.8) 91.0 (82.695.6) 92.3 (79.797.3)
8.2 (67.885.9) 56.4 (41.070.7) 66.7 (55.676.1)
1.0 (81.895.8) 80.7 (71.287.6) 94.5 (79.797.3)
6.0 (52.277.6) 75.9 (57.987.8) 58.1 (45.769.5)
.08 (2.4110.71) 2.09 (1.453.00) 8.67 (2.8926.00)
.26 (0.170.40) 0.16 (0.070.34) 0.36 (0.260.50)
80.3 79.5 75.2
ll classified, 78.6% Well classified, 89.2% Well classified, 78.5%
previous column 1.08 2.06
91.0 (82.695.6) 92.3 (79.797.3)
64.1 (48.477.3) 75.6 (65.183.8)
83.5 (74.289.9) 95.2 (86.798.3)
78.1 (61.289.0) 65.5 (52.376.6)
2.54(1.663.88) 9.83 (3.2929.38)
0.14 (0.070.30) 0.26 (0.180.39)
82.1 81.2
previous column Well classified, 89.3% Well classified, 78.6%
previous column 0.06 0.83
91.0 (82.695.6) 92.3 (79.797.3)
74.4 (58.985.4) 82.1 (72.189.0)
87.7 (78.793.2) 95.5 (87.698.5)
80.6 (65.090.2) 72.0 (58.382.5)
3.55 (2.076.09) 10.67 (3.5831.79)
0.12 (0.060.25) 0.19 (0.120.32)
85.5 85.5
previous column Well classified, 91.1% Well classified, 85.7%
; P  .087 vs LS.s f
C

8
7
9
6
5
0
We
See
See
See
Seeified as having or not CSPH. 289
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T3
F4EVs
In the training set, 37 of 117 (32%) patients had
EVs. In the validation set 33 of 56 (59%) patients had EVs.
All patients with varices had CSPH.
In the training set (Supplementary Table 1) patients
with and without varices differed in albumin, INR, Child-
Pugh score, spleen diameter, platelet count, LS, platelet to
spleen ratio, spleen to platelet ratio, and LSPS. Because
LSPS includes spleen diameter, platelet count, and LS, we
performed the multivariate analysis, including albumin,
INR (and/or ChildPugh score), spleen diameter, platelet
count, and LS. In this step, spleen diameter, platelet
count, and LS were maintained in the model. Then we
added the first- and second-grade interaction terms of
these 3 variables, that is, spleen diameter platelet count;
pleen diameter  LS; platelet count  LS and spleen
iameter  platelet count  LS. By this method, a hier-
rchical model including spleen diameter, platelet count,
S, and platelet count  LS was calculated as follows:
varices risk score  4.364  0.538  spleen diameter
 0.049  platelet count  0.044  LS 0.001  (LS 
platelet count).
The performance of the studied noninvasive parameters
(Figure 3) and of the new model (the varices risk score) for
dentifying EVs expressed as AUROC was as follows: platelet
ount: 0.761 (95% CI, 0.6740.935; P  .0001); spleen di-
meter: 0.785 (95% CI, 0.7000.856; P  .0001); LS: 0.794
95% CI, 0.7090.863; P  .0001); platelet count to spleen
atio: 0.814 (95% CI, 0.7320.880; P  .0001); LSPS 0.882
95% CI, 0.8100.935; P  .0001); varices risk score: 0.909
Figure 1. Prediction of CSPH in the training set. ROC curves of previ-
ously described noninvasive parameters and of the PH risk score for
identifying CSPH. As shown, PH risk score, LSPS, and LS had the best
diagnostic performance (De Long test: PH risk score vs LS P  .021;
LSPS vs LS P  .087; PH risk score vs LSPS P  .160).95% CI, 0.8410.954; P  .0001). Similar results were ob-ained when data were analyzed according to the etiology of
iver disease.
As shown in Table 3 and Figure 3, LSPS and varices risk
core had very high discriminative ability in predicting
arices. The analysis of the performance of previously
ublished cutoffs of noninvasive variables disclosed that
he 3.5 (sensitivity, 75.5%; 95% CI, 59.986.6; specificity,
8.8%; 95% CI, 80.593.8) and 5.5 (sensitivity, 43.2%; 95%
I, 28.759.1; Specificity 91.0%; 95% CI, 83.395.4) cut-
ffs of LSPS were not accurate enough for predicting or
xcluding the presence of varices (combined accuracy of
5.3%). Based on the analysis of the ROC curve, we here
ropose a new cutoff of LSPS, namely 3.21, with a good
ccuracy in both the training set (84.6%) and validation
et (75%) (Figure 4).
Discussion
In recent years, the availability of noninvasive tools
increased the proportion of patients with chronic liver
disease diagnosed in the compensated stage of cirrho-
sis.32,33 Because these patients, despite being completely
symptomatic, are those at risk of decompensation and
equire endoscopic screening for varices, objective and
ccurate noninvasive predictors of portal hypertension
nd EVs are especially needed.5
In this study, we confirm that, among the available and
routinely used noninvasive methods, LS is the single bet-
ter marker of CSPH, as assessed by the accepted gold
standard, ie, HVPG measurement. We further demon-
strate that its performance can be improved by combining
it with platelet count and spleen size into a single param-
eter, the PH risk score, which had a very good diagnostic
accuracy in both the training set and validation cohort
from another European country. In this regard, it should
be noted that PH risk score and LSPS (the first attempt at
integrating empirically values of LS and spleen diameter
to platelet count reported by Kim and colleagues to pre-
dict EVs in patients with hepatitis B virusrelated
chronic liver disease20) both show excellent AUROCs,
which are similar from a statistical point of view. How-
ever, when applying the best cutoffs of the curves, PH risk
score, calculated through a robust statistical analysis of
the noninvasive parameters of our training set, further
improved the performance as compared with LSPS by
reducing the proportion of indeterminate findings (12%
in the training set and 5% in the validation set). Certainly,
such a predictive value, pointed out by an AUROC of 0.93
in the training and validation cohorts, is almost impossi-
ble to improve in clinical practice and allows substituting
the measurement of HVPG in detecting CSPH. The rele-
vance of this finding relates to the fact that patients with
CSPH are at a much higher risk of developing varices,
clinical decompensation, and hepatocellular carcinoma
than compensated cirrhotic without CSPH. Therefore,
being able to accurately predict if a patient belongs to
such a higher-risk group has direct clinical implications. 347
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404As for the remaining noninvasive variables, none of
them allowed an accurate enough prediction of CSPH;
interestingly, a model based on laboratory variables (albu-
min, INR, and alanine aminotransferase) published by our
group17 did not perform well in the present cohort com-
posed of patients with chronic liver disease of different
etiologies, although it confirmed a high discriminative
power in the validation set, which was composed mainly
of HCV patients as the population from which the model
was derived.
Regarding the study population, we decided to include
patients with a single hepatic nodule potentially suscep-
tible to resection because in them the prediction of CSPH
is central and changes the clinical management.3,23 Al-
though in this subpopulation, most noninvasive parameters
have a reduced diagnostic accuracy, the PH risk score wasstill able to predict CSPH with an AUROC 0.85, even in
his subgroup of “difficult” patients. The PH risk score has
he advantage of not being significantly influenced by the
tiology of cirrhosis or the presence of liver nodules.
As for the prediction of the presence of EVs, LSPS had
good diagnostic performance, with accuracy of 85% in
he training set and 76% in the validation set, similar to
hat of our model-derived varices risk score. This combi-
ation of parameters was clearly superior to the perfor-
ance of LS alone for predicting EV. Interestingly enough,
hile diagnostic accuracy of LSPS by AUROC was similar to
hat published by Kim et al,20 the cutoffs of the original
publication were not accurate in our population; we specu-
late that this might depend on the different etiologies of the
included patients (hepatitis B virus in the original publica-
Figure 2. Performance of the
chosen cutoffs of noninvasive
variables for predicting CSPH.
Performance of binary cutoffs (A)
and of the use of 2 cutoffs (one
to rule out CSPH, and one to rule
in CSPH) (B) of LS, LSPS, and
PH risk score for the identifica-
tion of CSPH in the training set
(TS) and in the validation set
(VS). By using 2 cutoffs, PH risk
score showed the best perfor-
mance with low proportion of
misclassified patients, and lower
proportion of indeterminate
cases (McNemarBowker test:
PH risk score vs LS:P .0001 in
the TS and in the VS; PH risk
score vs LSPS: P  .025 in the
TS and P  .016 in the VS).tion, various etiologies in the present). Of note also, all 405
bP  .05 vs spleen diameter, platelet count, and platelet to spleen ratio
o
s
mance (by De Long test: LSPS vs LS P .010; varices risk score vs LS
P  .002; varices risk score vs LSPS P  .181).
C
LIN
IC
A
L
LIV
ER
8 BERZIGOTTI ET AL GASTROENTEROLOGY Vol. xx, No. x
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
C
O
L
O
R
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462remaining noninvasive variables, either used alone (spleen
size, platelet count, LS) or in combination (platelet to spleen
ratio), had an overall accuracy80%, which is the minimum
recommended for a diagnostic test. It is important to stress
that being able to predict varices cannot be translated di-
rectly into number of endoscopies saved because the predic-
tion does not extend to endoscopic signs of high-risk varices
(big in size and/or with presence or red color signs over their
wall). However, endoscopy can probably be obviated or de-
layed in patients with low predicted probability of varices.
This study suffers some potential limitations. First, we
included in both the training set and the validation co-
hort only patients consecutively observed with valid mea-
surements of LS, platelet count, and spleen size. There-
fore, our results have been obtained according to a “per
diagnostic protocol” analysis, and do not completely re-
flect the real-life situation in which technical failures of
the tests might occur. Indeed, in the training set, 14
patients (10.6%) originally evaluated were excluded due to
technical failure of transient elastography, confirming
previous observations.19 New transient elastography
probes (XL probe), as well as new sonoelastography
methods, might overcome this limitation of transient
elastography,34 with the added advantage of improving
the applicability of measurement of spleen stiffness,
ethods for Identifying Esophageal Varices in the Training
Cutoff with 80%
Specificity, %
Sensitivity, %
PPV, %
NPV, %
LR
LR
Well classified, %
Cutoff with 90%
Sensitivity, %
Specificity, %
PPV, %
NPV, %
LR
LR
Well classified, %
Cutoff with 90%
Specificity, %
Sensitivity, %
PPV, %
NPV, %
LR
LR
Well classified, %
2.94 2.06 3.85
80.0 (70.087.3) 91.9 (78.797.2%) 90.0 (81.594.8)
83.8 (68.992.3) 65.0 (54.174.5) 70.3 (54.282.5)
66.0 (51.777.8) 54.8 (42.566.6) 76.5 (60.087.6)
91.4 (82.596.0) 94.5 (85.198.1) 86.(77.892.4)
4.19 (2.646.64) 2.63 (1.923.59) 7.03 (3.5314.01)
0.20 (0.100.43) 0.13 (0.040.37) 0.33 (0.200.55)
81.2 73.5 83.8
ll classified, 75.0% Well classified, 76.8% Well classified, 69.6%
0.40 0.71 0.20
80.0 (70.087.3) 91.9 (78.797.2) 90.0 (81.594.8)
83.8 (68.992.3) 77.5 (67.285.3) 70.3 (54.294.8)
66.0 (51.777.8) 65.4 (51.876.8) 76.5 (60.087.6)
91.4 (82.596.0) 95.4 (87.398.4) 86.7 (77.892.4)
4.19 (2.646.64) 4.08 (2.696.20) 7.03 (3.5314.01)
0.20 (0.100.43) 0.10 (0.030.31) 0.33 (0.200.54)
81.2 82.1 83.8
ll classified, 76.8% Well classified, 75.0% Well classified, 72.6%Table 3. Performance of the Best Combinations of Noninvasive M
Set (N  117) and in the Validation Set (N  56)
AUROC for predicting EV
(95% CI)
Cutoff with 80%
Sensitivity, %
Specificity, %
PPV, %
NPV, %
LR
LR
Well classified, %
LSPS20
Training set 0.882a (0.8100.935) 3.21
P  .0001 81.1 (65.890.5)
86.3 (77.092.1)
73.2 (58.184.3)
90.8 (82.295.5)
5.90 (3.3310.43)
0.22 (0.110.43)
84.6
Validation set 0.808 (0.6930.923) Well classified, 75.0% We
Varices risk score P  .0001
Training set 0.909b (0.8410.954) 0.16
P  .0001 81.1 (65.890.5)
86.3 (77.092.1)
73.2 (58.184.3)
90.8 (82.295.5)
5.90 (3.3310.43)
0.22 (0.110.43)
84.6
Validation set 0.759 (0.6270.891) Well classified, 75.0% We
P  .0001
NPV, negative predictive value; PPV, positive predictive value.
De Long test:
aP  .05 vs spleen diameter, platelet count, and liver stiffness.Figure 3. Prediction of varices in the training set. ROC curves of previ-
usly described noninvasive parameters for predicting varices. As
hown, LSPS and varices risk score had the best diagnostic perfor-and LS. 463
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520which is emerging as a novel noninvasive parameter
closely correlating with HVPG and presence of EVs.35,36
Second, the prevalence of EVs in our population of
compensated patients was relatively low, which might
represent a bias for the generalizability of our results37;
owever, the prevalence of varices in the validation
ohort was exactly as anticipated. It should also be
oted that patients included in the training set and in
he validation set differed in a number of characteris-
ics; however, the similar results obtained by applying
ur models in the validation set further confirms the
obustness of our findings. Finally, we acknowledge
hat PH risk score and varices risk score are more
ifficult to calculate than LSPS at the bedside. In order
o reduce the impact of this limitation, we have made a
alculator available online (www.ciberehd.org/platforms-
nd-services/calculator?set_languageen) in which data can
e easily introduced and the individual probability of CSPH
nd of EV can be instantaneously visualized.
In conclusion, LS combined with spleen diameter and
latelet count (either as LSPS or our new model-derived
H risk score) allows a highly accurate noninvasive iden-
ification of CSPH in patients with compensated cirrhosis.
resence of EVs in patients with compensated cirrhosis of
ifferent etiologies can also be determined accurately
nough by a varices risk score and LSPS, but cutoffs of the
atter in our population are different than those previ-
usly published.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at http://
x.doi.org/10.1053/j.gastro.2012.10.001.
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634Supplementary Table 1. Main Characteristics of Patients
Included in the Training Set
According to the Presence of
Esophageal Varices
Patients with
varices
(n  37)
Patients without
varices
(n  80) P value
ge, y 59  12 60  9 .435
ody mass indexa 27.7  4.2 26.2 4.9 .340
Sex, M/F, n 24/13 58/22 .209
Etiology, HCV/HBV/
alcohol/other
24/1/6/6 54/10/10/6 .137
Child–Pugh score 5.9 1.0 5.3 0.6 .001
AST, U/L 89  48 79  56 .405
ALT, U/L 75  38 81  57 .663
Bilirubin, mg/dL 1.4  0.8 1.0 0.9 .033
INR 1.25  0.18 1.12 0.12 .0001
Albumin, g/dL 3.5  0.4 4.0 0.6 .0001
HVPG, mm Hg 16.8  4.4 9.61 4.3 .0001
Platelets, n3/mmc 104  61 152 59 .0001
Liver stiffness, kPa 36.3  18.2 20.1 13.0 .0001
Spleen diameter,
cm
15.2  3.6 12.1 2.1 .0001
Platelet to spleen
ratio
749  587 1336 680 .0001
Spleen to platelet
ratio
0.198  0.130 0.094 0.046 .0001
LSPS 6.67 5.07 2.09 2.09 .0001
Varices risk score 0.96 2.16 4.00  3.39 .0001
NOTE. Values are mean  standard deviation unless otherwise indi-
cated.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; F,
female; HBV, hepatitis B virus; HCV, hepatitis C virus; M, male.
aCalculated as kg/m2.635
